You are here: Industry Insights > SCD

News List

U.S. FDA Approves Supplemental New Drug Application for Expanded Indication of Oxbryta (voxelotor) for Children as Young as 4 Years of Age with Sickle Cell Disease Drugs
December 20, 2021
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval of a supplemental New Drug Application (sNDA) for Oxbryta...
Hemanext Partners with Sickle Cell 101 to Sponsor Sickle Cell Education prnasia
July 29, 2021
Hemanext Inc. a privately held, US-based medical technology company dedicated to improving the quality, safety, efficacy, and cost of red blood cell (RBC) transfusions, has partnered with Sickle Cell 101 (SC101), a Silicon Valley-based non-profit, to ...
What Diet Is Most Likely to Help Ease Crohn's Disease? drugs
June 09, 2021
People who have Crohn's disease often seek to ease their symptoms by changing what they eat, and new research suggests the Mediterranean diet may be their best bet.
Could this Novartis initiative finally cure sickle cell disease? pharmaceutical-technology
June 04, 2021
If you want to better understand how our genes can predispose us to disease, look to sickle cell disorder (SCD). It’s one of the oldest known and most common genetic disorders and affects millions of people around the world.
Novartis, Gates Foundation to Develop Accessible Gene Therapy for Sickle Cell Disease americanpharmaceuticalreview
February 20, 2021
Novartis has entered into a grant agreement with the Bill & Melinda Gates Foundation. As part of the agreement, the foundation will provide funding support for the discovery and development of a single-administration, in vivo gene therapy to cure SCD.
EMA begins review of GBT's sickle cell treatment Oxbryta pharmatimes
January 29, 2021
The European Medicines Agency (EMA) has accepted a marketing authorisation application for Global Blood Therapeutic’s (GBT) Oxbryta (voxelotor).
Aruvant partners with Lonza to manufacture sickle cell disease treatment pharmaceutical-technology
January 20, 2021
Clinical-stage biopharmaceutical firm Aruvant Sciences and Lonza have entered a strategic long-term manufacturing agreement for the former’s one-time investigational gene therapy for sickle cell disease (SCD), ARU-1801.
HCATS, Apceth Expand Manufacturing Pact with Bluebird Bio contractpharma
May 12, 2020
Enter long-term development and manufacturing services agreements for clinical and commercial supply for multiple therapies.
Poor HIV Control Ups Risk for Sudden Cardiac Death in Heart Failure drugs
August 26, 2019
Persons living with HIV (PHIV) who are hospitalized with heart failure are at an increased risk for subsequent sudden cardiac death (SCD)...
Previous Silent MI Often Found at Autopsy in Sudden Cardiac Death drugs
July 30, 2019
Autopsies show that more than 40 percent of individuals who experience sudden cardiac death (SCD) associated with coronary artery disease (CAD) have had...

Previous page 1 2 Next page